With a heritage of more than 60 years in discovering and developing new therapeutic agents to protect and preserve vision, eye care professionals and patients rely on Allergan products to treat a variety of eye conditions including glaucoma, dry eye, and external eye diseases. Today we are a global leader in this specialty area. Leading products in Allergan's eye care product portfolio include RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution), and the REFRESH® Brand line of artificial tears.
Our robust research and development investment upholds our unwavering commitment to advancing eye care treatments. Back-of-the-eye diseases, such as macular edema, diabetic retinopathy and age-related macular degeneration, cause sight loss in millions of patients each year. Unfortunately, the prevalence of these diseases is increasing as the population ages. Over the next decade, major progress will be made in treating such retinal diseases and Allergan expects to be in the forefront of these advances.